Complete molecular response (CMR) rate With nilotinib in patients (pts) With chronic myeloid leukemia in chronic phase (CML-CP) without CMR after ≥ 2 Years on imatinib : preliminary results from the randomized ENESTcmr trial of nilotinib 400 mg twice da

Authors
Publication date
1 November 2011
Publisher
'American Society of Hematology'

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Deakin Research Online

    redirect
    oaioai:dro.deakin.edu.au:DU:30060...
    Last time updated on 27/02/2014